The problem
Breast and lung cancers caught late are far deadlier, but reading every scan needs radiologists the world doesn’t have. In developing markets the gap is worst: Thailand and Indonesia lack organized cancer-screening infrastructure, so treatable tumors surface only when it’s too late.
How it works
Lunit’s INSIGHT products plug into existing radiology workflows: INSIGHT CXR triages chest X-rays across 10 common findings, INSIGHT MMG (plus DBT for 3D mammography) flags suspicious breast lesions, and SCOPE analyzes tissue-slide images across 15+ cancer types to predict immunotherapy response. The May 2024 Volpara acquisition added precise breast-density measurement and a dataset of 117M+ medical images for building universal screening models. Distribution runs through partners hospitals already trust — GE Healthcare, Fujifilm, Philips, Guardant Health.
Pain points
Screening backlogs and physician overload, inconsistent early detection across ethnicities and machines, and entire countries where women avoid or cannot access mammography screening.
Business model
Regulated SaaS: annual licenses per site or per scan, sold direct and embedded in OEM imaging equipment and partner platforms, with Volpara’s 2,000-site US footprint as the beachhead for American expansion.
Challenges
Each product needs its own FDA/CE clearance cycle; AI reimbursement codes lag the technology; and Siemens, Google, and a crowd of imaging-AI startups all chase the same radiology budget.
Funding
- Raised: $60M venture round (late 2021, pre-IPO); $150M paid-in capital increase (Nov 2023, >100% shareholder participation) earmarked for next-generation products, global talent, overseas subsidiaries, and a strategic CVC arm.
- Deployed: ₩264.7B ($191.3M) to acquire 100% of New Zealand’s Volpara Health Technologies (deal signed Dec 2023, closed May 2024; Volpara delisted from the ASX).
- Valuation: ≈$320M market cap at the July 2022 Kosdaq debut.
Latest — July 2024
CEO Brandon Suh told The Korea Economic Daily that Lunit will push into developing markets after its US/Europe wins — detailed pilot plans for AI breast-screening programs in Southeast Asia and the Middle East, drawn up after talks with Thai and Indonesian officials at Summer Davos, launching within a year.